# Spyre Therapeutics, Inc.: financial statements, quarterly

SYRE · Nasdaq · CIK 1636282 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/syre.md) · [Financials](/companies/syre/financials.md) · [Filings](/companies/syre/filings.md) · [Insiders](/companies/syre/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/syre/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001636282-24-000113.md) | [0.0 d](/filings/0001636282-26-000020.md) | [0.0](/filings/0001636282-24-000109.md) | [0.0](/filings/0001636282-24-000111.md) | [0.0](/filings/0001636282-24-000113.md) | [0.0 d](/filings/0001636282-26-000020.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(18.3)](/filings/0001636282-24-000113.md) | [(45.9) d](/filings/0001636282-26-000020.md) | [(47.8)](/filings/0001636282-25-000049.md) | [(44.1)](/filings/0001636282-25-000089.md) | [(55.4)](/filings/0001636282-25-000102.md) | [(61.3) d](/filings/0001636282-26-000020.md) | [(53.6)](/filings/0001636282-26-000050.md) | [(41.9)](/filings/0001636282-26-000096.md) | [(56.9)](/filings/0001636282-25-000102.md) | [(57.2) d](/filings/0001636282-26-000020.md) | [(45.6)](/filings/0001636282-26-000050.md) | [(41.6)](/filings/0001636282-26-000096.md) |
| Income tax | $m | [0.0](/filings/0001636282-24-000113.md) | [0.0 d](/filings/0001636282-26-000020.md) | [0.0](/filings/0001636282-25-000049.md) | [0.0](/filings/0001636282-25-000089.md) | [0.0](/filings/0001636282-25-000102.md) | [0.0 d](/filings/0001636282-26-000020.md) | [(0.0)](/filings/0001636282-26-000050.md) | [0.0](/filings/0001636282-26-000096.md) | [0.0](/filings/0001636282-25-000102.md) | [0.0 d](/filings/0001636282-26-000020.md) | [0.0](/filings/0001636282-26-000050.md) | [0.0](/filings/0001636282-26-000096.md) |
| Net income | $m | [(40.1)](/filings/0001636282-24-000113.md) | [(63.2) d](/filings/0001636282-26-000020.md) | [(43.9)](/filings/0001636282-25-000102.md) | [(38.8)](/filings/0001636282-25-000102.md) | [(69.0)](/filings/0001636282-25-000102.md) | [(56.3) d](/filings/0001636282-26-000020.md) | [(44.8)](/filings/0001636282-26-000096.md) | [(36.7)](/filings/0001636282-26-000096.md) | [(11.2)](/filings/0001636282-25-000102.md) | [(62.5) d](/filings/0001636282-26-000020.md) | [(69.0)](/filings/0001636282-26-000096.md) | [(36.2)](/filings/0001636282-26-000096.md) |
| Diluted EPS | $ per share | [0.86](/filings/0001636282-24-000113.md) | not reported | [0.72](/filings/0001636282-24-000109.md) | [0.59](/filings/0001636282-24-000111.md) | [1.06](/filings/0001636282-24-000113.md) | not reported | not reported | not reported | not reported | not reported | [(0.74)](/filings/0001636282-26-000050.md) | not reported |
| Basic EPS | $ per share | [0.86](/filings/0001636282-24-000113.md) | not reported | [0.72](/filings/0001636282-24-000109.md) | [0.59](/filings/0001636282-24-000111.md) | [1.06](/filings/0001636282-24-000113.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [90.6](/filings/0001636282-24-000113.md) | [189](/filings/0001636282-26-000020.md) | [228](/filings/0001636282-25-000049.md) | [45.1](/filings/0001636282-25-000089.md) | [71.6](/filings/0001636282-24-000113.md) | [89.4](/filings/0001636282-26-000020.md) | [48.5](/filings/0001636282-25-000049.md) | [81.7](/filings/0001636282-25-000089.md) | [64.9](/filings/0001636282-25-000102.md) | [85.7](/filings/0001636282-26-000096.md) | [97.2](/filings/0001636282-26-000050.md) | [162](/filings/0001636282-26-000096.md) |
| Current assets | $m | [206](/filings/0001636282-23-000018.md) | [342](/filings/0001636282-25-000020.md) | [487](/filings/0001636282-24-000109.md) | [436](/filings/0001636282-24-000111.md) | [421](/filings/0001636282-24-000113.md) | [608](/filings/0001636282-26-000020.md) | [570](/filings/0001636282-25-000049.md) | [539](/filings/0001636282-25-000089.md) | [505](/filings/0001636282-25-000102.md) | [778](/filings/0001636282-26-000096.md) | [764](/filings/0001636282-26-000050.md) | [1,173](/filings/0001636282-26-000096.md) |
| Total assets | $m | [207](/filings/0001636282-23-000018.md) | [342](/filings/0001636282-25-000020.md) | [488](/filings/0001636282-24-000109.md) | [436](/filings/0001636282-24-000111.md) | [421](/filings/0001636282-24-000113.md) | [608](/filings/0001636282-26-000020.md) | [570](/filings/0001636282-25-000049.md) | [539](/filings/0001636282-25-000089.md) | [505](/filings/0001636282-25-000102.md) | [778](/filings/0001636282-26-000096.md) | [764](/filings/0001636282-26-000050.md) | [1,173](/filings/0001636282-26-000096.md) |
| Current liabilities | $m | [44.9](/filings/0001636282-23-000018.md) | [32.0](/filings/0001636282-25-000020.md) | [42.8](/filings/0001636282-24-000109.md) | [22.1](/filings/0001636282-24-000111.md) | [57.5](/filings/0001636282-24-000113.md) | [54.1](/filings/0001636282-26-000020.md) | [70.7](/filings/0001636282-25-000049.md) | [83.1](/filings/0001636282-25-000089.md) | [46.3](/filings/0001636282-25-000102.md) | [58.7](/filings/0001636282-26-000096.md) | [85.2](/filings/0001636282-26-000050.md) | [63.3](/filings/0001636282-26-000096.md) |
| Total liabilities | $m | [65.6](/filings/0001636282-23-000018.md) | [73.3](/filings/0001636282-25-000020.md) | [81.9](/filings/0001636282-24-000109.md) | [61.7](/filings/0001636282-24-000111.md) | [93.7](/filings/0001636282-24-000113.md) | [90.7](/filings/0001636282-26-000020.md) | [87.2](/filings/0001636282-25-000049.md) | [83.1](/filings/0001636282-25-000089.md) | [49.5](/filings/0001636282-25-000102.md) | [62.5](/filings/0001636282-26-000096.md) | [93.1](/filings/0001636282-26-000050.md) | [71.9](/filings/0001636282-26-000096.md) |
| Shareholders' equity | $m | [(245)](/filings/0001636282-24-000113.md) | [184](/filings/0001636282-26-000020.md) | [152](/filings/0001636282-25-000102.md) | [374](/filings/0001636282-25-000102.md) | [327](/filings/0001636282-25-000102.md) | [518](/filings/0001636282-26-000096.md) | [483](/filings/0001636282-26-000096.md) | [456](/filings/0001636282-26-000096.md) | [455](/filings/0001636282-25-000102.md) | [715](/filings/0001636282-26-000096.md) | [671](/filings/0001636282-26-000096.md) | [1,101](/filings/0001636282-26-000096.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(34.6) d](/filings/0001636282-24-000113.md) | [(31.0) d](/filings/0001636282-26-000020.md) | [(28.5)](/filings/0001636282-25-000049.md) | [(62.2) d](/filings/0001636282-25-000089.md) | [(29.4) d](/filings/0001636282-25-000102.md) | [(37.2) d](/filings/0001636282-26-000020.md) | [(41.0)](/filings/0001636282-26-000050.md) | [(46.6) d](/filings/0001636282-26-000096.md) | [(37.1) d](/filings/0001636282-25-000102.md) | [(44.6) d](/filings/0001636282-26-000020.md) | [(57.4)](/filings/0001636282-26-000050.md) | [(69.9) d](/filings/0001636282-26-000096.md) |
| Capital expenditure | $m | not reported | [0.0 d](/filings/0001636282-25-000020.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [65.6](/filings/0001564590-22-027895.md) | [65.8](/filings/0000950170-22-021529.md) | [66.0](/filings/0000950170-23-020825.md) | [82.2](/filings/0000950170-23-041590.md) | [3.8](/filings/0001636282-23-000018.md) | [3.8](/filings/0001636282-24-000109.md) | [3.8](/filings/0001636282-24-000111.md) | [4.3](/filings/0001636282-24-000113.md) | [36.5](/filings/0001636282-24-000109.md) | [45.3](/filings/0001636282-24-000111.md) | [50.9](/filings/0001636282-24-000113.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 88,173,762 at 2026-07-28, from the cover of the [10-Q filed 2026-08-04](/filings/0001636282-26-000096.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.